Global Endometriosis Market Overview And Scope:
Global Endometriosis Market Size was estimated at USD 1538.83 million in 2022 and is projected to reach USD 1674.08 million by 2028, exhibiting a CAGR of 1.41% during the forecast period.
The Global Endometriosis Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Endometriosis utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, EndoCeutics, Euroscreen, Forendo Pharma, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, Takeda, Bayer AG, Neurocrine Biosciences
Global Endometriosis Market Segmentation
By Type, Endometriosis market has been segmented into:Gonadotropins Releasing Hormone Agonists
Non-Steroidal Anti-Inflammatory Drugs
Progestin
Oral Contraceptive Pills
By Application, Endometriosis market has been segmented into:
Hospital Use
Clinic Use
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Endometriosis market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Endometriosis market.
Top Key Players Covered in Endometriosis market are:
AbbVie
AstraZeneca
Bayer HealthCare
Pfizer
Addex Therapeutics
Astellas Pharma
Debiopharm
ElexoPharm
EndoCeutics
Euroscreen
Forendo Pharma
Kissei Pharmaceutical
Neurocrine Biosciences
Nippon Shinyaku
Takeda
Bayer AG
Neurocrine Biosciences
Objective to buy this Report:
1. Endometriosis analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Endometriosis market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Endometriosis Market by Type
5.1 Endometriosis Market Overview Snapshot and Growth Engine
5.2 Endometriosis Market Overview
5.3 Gonadotropins Releasing Hormone Agonists
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Gonadotropins Releasing Hormone Agonists: Geographic Segmentation
5.4 Non-Steroidal Anti-Inflammatory Drugs
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Non-Steroidal Anti-Inflammatory Drugs: Geographic Segmentation
5.5 Progestin
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Progestin: Geographic Segmentation
5.6 Oral Contraceptive Pills
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Oral Contraceptive Pills: Geographic Segmentation
Chapter 6: Endometriosis Market by Application
6.1 Endometriosis Market Overview Snapshot and Growth Engine
6.2 Endometriosis Market Overview
6.3 Hospital Use
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Use: Geographic Segmentation
6.4 Clinic Use
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Clinic Use: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Endometriosis Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Endometriosis Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Endometriosis Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ABBVIE
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 ASTRAZENECA
7.4 BAYER HEALTHCARE
7.5 PFIZER
7.6 ADDEX THERAPEUTICS
7.7 ASTELLAS PHARMA
7.8 DEBIOPHARM
7.9 ELEXOPHARM
7.10 ENDOCEUTICS
7.11 EUROSCREEN
7.12 FORENDO PHARMA
7.13 KISSEI PHARMACEUTICAL
7.14 NEUROCRINE BIOSCIENCES
7.15 NIPPON SHINYAKU
7.16 TAKEDA
7.17 BAYER AG
7.18 NEUROCRINE BIOSCIENCES
Chapter 8: Global Endometriosis Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Gonadotropins Releasing Hormone Agonists
8.2.2 Non-Steroidal Anti-Inflammatory Drugs
8.2.3 Progestin
8.2.4 Oral Contraceptive Pills
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital Use
8.3.2 Clinic Use
8.3.3 Other
Chapter 9: North America Endometriosis Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Gonadotropins Releasing Hormone Agonists
9.4.2 Non-Steroidal Anti-Inflammatory Drugs
9.4.3 Progestin
9.4.4 Oral Contraceptive Pills
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital Use
9.5.2 Clinic Use
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Endometriosis Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Gonadotropins Releasing Hormone Agonists
10.4.2 Non-Steroidal Anti-Inflammatory Drugs
10.4.3 Progestin
10.4.4 Oral Contraceptive Pills
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital Use
10.5.2 Clinic Use
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Endometriosis Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Gonadotropins Releasing Hormone Agonists
11.4.2 Non-Steroidal Anti-Inflammatory Drugs
11.4.3 Progestin
11.4.4 Oral Contraceptive Pills
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital Use
11.5.2 Clinic Use
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Endometriosis Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Gonadotropins Releasing Hormone Agonists
12.4.2 Non-Steroidal Anti-Inflammatory Drugs
12.4.3 Progestin
12.4.4 Oral Contraceptive Pills
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital Use
12.5.2 Clinic Use
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Endometriosis Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Gonadotropins Releasing Hormone Agonists
13.4.2 Non-Steroidal Anti-Inflammatory Drugs
13.4.3 Progestin
13.4.4 Oral Contraceptive Pills
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital Use
13.5.2 Clinic Use
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Endometriosis Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Gonadotropins Releasing Hormone Agonists
14.4.2 Non-Steroidal Anti-Inflammatory Drugs
14.4.3 Progestin
14.4.4 Oral Contraceptive Pills
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospital Use
14.5.2 Clinic Use
14.5.3 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Endometriosis Scope:
|
Report Data
|
Endometriosis Market
|
|
Endometriosis Market Size in 2025
|
USD XX million
|
|
Endometriosis CAGR 2025 - 2032
|
XX%
|
|
Endometriosis Base Year
|
2024
|
|
Endometriosis Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, EndoCeutics, Euroscreen, Forendo Pharma, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, Takeda, Bayer AG, Neurocrine Biosciences.
|
|
Key Segments
|
By Type
Gonadotropins Releasing Hormone Agonists
Non-Steroidal Anti-Inflammatory Drugs
Progestin
Oral Contraceptive Pills
By Applications
Hospital Use
Clinic Use
Other
|
